To independently and externally validate the Brain Tumour Reporting and Data System (BT-RADS) for post-treatment gliomas and assess interobserver variability.

Material and methods:
In this retrospective observational study, consecutive MRIs of 100 post-treatment glioma patients were reviewed by two independent radiologists (RD1 and RD2) and assigned a BT-RADS score. Inter-observer agreement statistics were determined by kappa statistics. The BT-RADS-linked management recommendations per score were compared with the multidisciplinary meeting (MDM) decisions.

The overall agreement rate between RD1 and RD2 was 62.7% (κ = 0.67). The agreement rate between RD1 and consensus was 83.3% (κ = 0.85), while the agreement between RD2 and consensus was 69.3% (κ = 0.79). Among the radiologists, agreement was highest for score 2 and lowest for score 3b. There was a 97.9% agreement between BT-RADS-linked management recommendations and MDM decisions.

BT-RADS scoring led to improved consistency, and standardised language in the structured MRI reporting of post-treatment brain tumours. It demonstrated good overall agreement among the reporting radiologists at both extremes; however, variation rates increased in the middle part of the spectrum. The interpretation categories linked to management decisions showed a near-perfect match with MDM decisions.

Claus EB, Walsh KM, Wiencke JK, et al. Survival and low-grade glioma: the emergence of genetic information. Neurosurg Focus 2015; 38: E6. doi: 10.3171/2014.10.FOCUS12367.
Crooms RC, Goldstein NE, Diamond EL, et al. Palliative care in high-grade glioma: a review. Brain Sci 2020; 10: 723. doi: 10.3390/brainsci10100723.
Smits M, van den Bent MJ. Imaging correlates of adult glioma geno­types. Radiology 2017; 284: 316-331.
Sahu A, Patnam NG, Goda JS, et al. Multiparametric magnetic resonance imaging correlates of isocitrate dehydrogenase mutation in WHO high-grade astrocytomas. J Pers Med 2022; 13: 72. doi: 10.3390/jpm13010072.
Kessler AT, Bhatt AA. Brain tumour post-treatment imaging and treatment-related complications. Insights into Imaging 2018; 9: 1057-1075.
Macdonald DR, Cascino TL, Schold SC Jr, et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8: 1277-1280.
Tensaouti F, Khalifa J, Lusque A, et al. Response assessment in neuro-oncology criteria, contrast enhancement and perfusion MRI for assessing progression in glioblastoma. Neuroradiology 2017; 59: 1013-1020.
Weinberg BD, Gore A, Shu HKG, et al. Management-based structured reporting of posttreatment glioma response with the brain tumor reporting and data system. J Am Coll Radiol 2018; 15: 767-771.
Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977: 159-174.
Cooper M, Hoch M, Abidi S, et al. NIMG-10. Brain tumor MRI structured reporting allows calculation of interrater agreement of patients reviewed at tumor board. Neuro Oncol 2019; 21 (Suppl 6): vi163. doi: 10.1093/neuonc/noz175.682.
Sahu A, Mathew R, Ashtekar R, et al. The complementary role of MRI and FET PET in high grade gliomas to differentiate recurrence from radionecrosis. Front Nucl Med 2023; 3: 1040998.
Gahramanov S, Muldoon LL, Varallyay CG, et al. Pseudoprogression of glioblastoma after chemo-and radiation therapy: diagnosis by using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging with ferumoxytol versus gadoteridol and correlation with survival. Radiology 2013; 266: 842-852.
Elmogy SA, Mousa AE, Elashry MS, et al. MR spectroscopy in post-treatment follow up of brain tumors. Egypt J Radiol Nucl Med 2011; 42: 413-424.
Journals System - logo
Scroll to top